课题基金 / 基金详情

High dose radiation therapy to direct immune responses to pancreatic cancer

High dose radiation therapy to direct immune responses to pancreatic cancer
高剂量放射治疗引导胰腺癌的免疫反应
批准号:
10676741
负责人:
Michael James Gough
金额:
$38.4万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-15 至 2024-05-31

项目摘要

项目成果

Michael James Gough的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY The critical preliminary data for this proposal is that in preclinical models, pre-existing tumor-resident T cells are both necessary and sufficient for tumor control by radiation therapy and immunotherapy. We demonstrate that in poorly immunogenic tumors, cross-presenting dendritic cells in the tumor-draining lymph node may be playing no significant role in tumor control. In these models, radiation and immunotherapy are an effective means of local control but fail to engender new systemic immunity. The aim of this proposal is to understand how radiation interacts with tumor resident T cells for local control, and how to restore cross-presentation of tumor-associated antigens to generate new systemic anti-tumor immune responses. We hypothesize that the endogenous vaccine effect of radiation therapy is limited in poorly immunogenic tumors, and current success relies on amplifying pre-existing anti-tumor immunity. The specific aims of this study are to 1: Test the hypothesis that in the presence of pre-existing immunity, tumor control by radiation therapy and immunotherapy occurs independent of cross-presentation and new immune responses; 2: Test the hypothesis that deficient DC cross-presentation limits the ability of radiation therapy to initiate new systemic anti-tumor immune responses; 3: Test the hypothesis that regulation of antigen presentation and cross-presenting DC can be assessed in patient tumors using genetic analysis. Our study design incorporates CT-guided radiation therapy and results are validated in multiple tumor models including those from genetically engineered spontaneous models, using a range of RT doses and fractionations. Our analyses of clinical samples use high quality bioinformatic approaches that allow us to evaluate the infiltrating immune cells and antigen presentation in patient tumors. These are applied to a unique clinical study that allows us to validate our preclinical observations in patients.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.2217/imt-2017-0056
发表时间: 2017-09
期刊: Immunotherapy
影响因子: 2.8
作者: [McGinnis GJ, Raber J]
通讯作者: Raber J
DOI: 10.18632/oncotarget.11823
发表时间: 2016-11-29
期刊: Oncotarget
影响因子: --
作者: [Crittenden MR, Baird J, Friedman D, Savage T, Uhde L, Alice A, Cottam B, Young K, Newell P, Nguyen C, Bambina S, Kramer G, Akporiaye E, Malecka A, Jackson A, Gough MJ]
通讯作者: Gough MJ
DOI: 10.4049/jimmunol.1700909
发表时间: 2018-01-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Alice AF, Kramer G, Bambina S, Baird JR, Bahjat KS, Gough MJ, Crittenden MR]
通讯作者: Crittenden MR
DOI: 10.1371/journal.pone.0157164
发表时间: 2016
期刊: PloS one
影响因子: 3.7
作者: [Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR]
通讯作者: Crittenden MR
7
    DNASE1L3 regulation of anti-tumor immune responses following radiation therapy
    Rewiring the myeloid cell response to adjuvants to improve tumor control
    • 批准号:
      10064141
    • 项目类别:
    • 资助金额:
      $37.74万
    • 财政年份:
      2019
    • 负责人:
      Michael James Gough
    • 依托单位:
    Rewiring the myeloid cell response to adjuvants to improve tumor control
    • 批准号:
      10534119
    • 项目类别:
    • 资助金额:
      $36.99万
    • 财政年份:
      2019
    • 负责人:
      Michael James Gough
    • 依托单位:
    Rewiring the myeloid cell response to adjuvants to improve tumor control
    • 批准号:
      10305679
    • 项目类别:
    • 资助金额:
      $36.99万
    • 财政年份:
      2019
    • 负责人:
      Michael James Gough
    • 依托单位:
    海外基金